{"cluster": 63, "subcluster": 2, "abstract_summ": "This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.Abstract No specific and effective anti-viral treatment has been approved for COVID-19 so far.Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients.In this setting, the existing drugs chloroquine (CQ) and hydroxychloroquine (HCQ) which has suggestive evidence of efficacy against SARS-CoV-2 infection and COVID-19 disease has become prime candidates to be repositioned as therapeutic and preventative agents, and a growing number of clinical trials have been registered to study their preventative potential for at-risk populations using a range of dosing schemes and outcome measures.There are also no clinical trial data supporting prophylactic HCQ therapy in COVID-19.Among these treatments, the off-label use of hydroxychloroquine (HCQ), a less toxic derivate of chloroquine, has become a common practice among clinicians, including pediatricians, despite lack of evidence of its clinical efficacy for this indication (especially for pediatric patients) at present time (2).", "title_summ": "Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three casesMeeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19Chloroquine and hydroxychloroquine in the context of COVID-19Reposition of Montelukast either alone or in combination with Levocetirizine against SARS-CoV-2Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?Rheumotologitsts\u2019 view on the use of hydroxychloroquine to treat COVID-19Efficacy, safety and cost\u2010effectiveness of hydroxychloroquine in children with COVID\u201019: A call for evidenceReply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?Hydroxychloroquine and covid-19.Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?Emergency Approval of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.Hydroxychloroquine use in the COVID-19 patient.Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.", "title_abstract_phrases": "This rapid systematic review protocol aims to provide streamlined and timely synthesis on methodologies and results of randomized controlled trials assessing the efficacy of CQ and HCQ in hopes that this will constructively inform further research as well as public health policy.[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments.This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three casesAbstract No specific and effective anti-viral treatment has been approved for COVID-19 so far.Emergency Approval of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019).In this setting, the existing drugs chloroquine (CQ) and hydroxychloroquine (HCQ) which has suggestive evidence of efficacy against SARS-CoV-2 infection and COVID-19 disease has become prime candidates to be repositioned as therapeutic and preventative agents, and a growing number of clinical trials have been registered to study their preventative potential for at-risk populations using a range of dosing schemes and outcome measures.Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients."}